, Volume 41, Issue 7, pp 630–638 | Cite as

Colchicine in addition to conventional therapy for pericarditis recurrence

An update meta-analysis
  • Y.-L. Li
  • S.-B. Qiao
  • J.-Y. Wang
  • Y.-M. Chen
  • J. Luo
  • H.-F. Zhang
Original articles



Randomized controlled trials (RCTs) have investigated the use of colchicine and conventional therapy for reducing the recurrence of pericarditis in patients with acute pericarditis or post-pericardiotomy syndrome. However, the benefits of these treatments are variable.


Studies were retrieved from PubMed, the Cochrane Library, and the EMBASE database.


We identified nine RCTs with 1832 patients and a mean follow-up of 13.1 months. Overall, colchicine therapy significantly decreased the risk of pericarditis recurrence (odds ratio, OR 0.42; 95 % confidence interval, CI 0.33–0.52; P < 0.001; I2 = 17.0 %). Colchicine therapy was associated with significantly lower rates of pericarditis-associated rehospitalization (OR 0.29; 95 % CI 0.16–0.53; P < 0.0001; I2 = 0.0 %) and persistence of symptoms (OR 0.29; 95 % CI, 0.21–0.41; P = 0.000; I2 = 0.0 %) at 72 h. Adverse events were higher in the colchicine group (relative risk, RR 1.48; 95 % CI, 1.06–2.07; P = 0.02; I2 = 0.0 %). Subgroup analysis showed that recurrence of pericarditis was significantly lower in the colchicine therapy group, irrespective of prednisone use and the cause of pericarditis.


Colchicine significantly decreases the rate of pericarditis recurrence, regardless of prednisone use and the cause of pericarditis. Larger studies are needed to confirm this effect.


Randomized controlled trials Post-pericardiotomy syndrome Recurrence Prednisone Adverse event 

Colchicin zusätzlich zur konventionellen Therapie bei Perikarditisrezidiv

Eine aktualisierte Metaanalyse



In randomisierten kontrollierten Studien (RCT) wurde der Einsatz von Colchicin und konventioneller Therapie untersucht, um das Risiko von Perikarditisrezidiven bei Patienten mit akuter Perikarditis oder Postperikardiotomiesyndrom zu senken. Der Nutzen dieser Behandlungen ist jedoch unterschiedlich.


Entsprechende Studien wurden in den Datenbanken PubMed, Cochrane Library und EMBASE gesucht.


Die Autoren fanden 9 RCT mit 1832 Patienten und einer durchschnittlichen Nachbeobachtungsdauer von 13,1 Monaten. Insgesamt senkte die Colchicintherapie das Risiko eines Perikarditisrezidivs signifikant (Odds Ratio, OR: 0,42; 95 %-Konfidenzintervall, 95%-KI: 0,33–0,52; p < 0,001; I2 = 17,0 %). Die Colchicintherapie ging mit einer signifikant niedrigeren Rate an perikarditisbedingten stationären Wiederaufnahmen (OR: 0,29; 95 %-KI: 0,16–0,53; p < 0,0001; I2 = 0,0 %) und an Symptompersistenz (OR: 0,29; 95 %-KI: 0,21–0,41; p = 0,000; I2 = 0,0 %) nach 72 h einher. Unerwünschte Ereignisse traten häufiger in der Colchicingruppe auf (relatives Risiko, RR: 1,48; 95 %-KI: 1,06–2,07; p = 0,02; I2 = 0,0 %). Die Subgruppenanalyse zeigte, dass Perikarditisrezidive in der Gruppe mit Colchicintherapie signifikant niedriger waren, unabhängig vom Einsatz von Prednison und von der Ursache der Perikarditis.


Colchicin senkt die Rate an Perikarditisrezidiven signifikant, ungeachtet des ggf. erfolgenden Prednisoneinsatzes und der Perikarditisursache. Größere Studien sind erforderlich, um dies zu bestätigen.


Randomisierte kontrollierte Studien Postperikardiotomiesyndrom Rezidiv Prednison Unerwünschtes Ereignis 


Compliance with ethical guidelines

Conflict of interest

Y.-L. Li, S.-B. Qiao, J.-Y. Wang, Y.-M. Chen, J. L., and H.-F. Zhang state that there are no conflicts of interest.

The accompanying manuscript does not include studies on humans or animals.


  1. 1.
    Crittenden DB, Pillinger MH (2013) New therapies for gout. Annu Rev Med 64:325–337CrossRefPubMedGoogle Scholar
  2. 2.
    Cocco G, Chu DC, Pandolfi S (2010) Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 21:503–508CrossRefPubMedGoogle Scholar
  3. 3.
    Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, Maestroni S, Zingarelli E, Barosi A, Simon C, Sansone F, Patrini D, Vitali E, Ferrazzi P, Spodick DH, Adler Y, COPPS Investigators (2010) Colchicine for the prevention of the post-pericardiotomy syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 31:2749–2754CrossRefPubMedGoogle Scholar
  4. 4.
    Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R (2005) Colchicine in addition to conventional therapy for acute pericarditis: results of the colchicine for acute pericarditis (COPE) trial. Circulation 112:2012–2016CrossRefPubMedGoogle Scholar
  5. 5.
    Imazio M, Brucato A, Trinchero R, Spodick D, Adler Y (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532–539CrossRefPubMedGoogle Scholar
  6. 6.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. J Clin Epidemiol 62:1006–1012CrossRefPubMedGoogle Scholar
  7. 7.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  8. 8.
    Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, Sharoni E, Sahar G, Smolinsky AK, Schechter T, Vidne BA, Adler Y (2002) Colchicine for the prevention of postpericardiotomy syndrome. Herz 27:791–794CrossRefPubMedGoogle Scholar
  9. 9.
    Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R (2005) Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (colchicine for recurrent pericarditis) trial. Arch Intern Med 165:1987–1991CrossRefPubMedGoogle Scholar
  10. 10.
    Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y, CORP (COlchicine for Recurrent Pericarditis) Investigators (2011) Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 155:409–414CrossRefPubMedGoogle Scholar
  11. 11.
    Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y, ICAP Investigators (2013) A randomized trial of colchicine for acute pericarditis. N Engl J Med 369:1522–1528CrossRefPubMedGoogle Scholar
  12. 12.
    Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, Cumetti D, Varbella F, Trinchero R, Spodick DH, Adler Y (2014) Efficacy and safety of colchicine for. treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 383:2232–2237CrossRefPubMedGoogle Scholar
  13. 13.
    Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, Caforio AL, Cemin R, Chirillo F, Comoglio C, Cugola D, Cumetti D, Dyrda O, Ferrua S, Finkelstein Y, Flocco R, Gandino A, Hoit B, Innocente F, Maestroni S, Musumeci F, Oh J, Pergolini A, Polizzi V, Ristic A, Simon C, Spodick DH, Tarzia V, Trimboli S, Valenti A, Belli R, Gaita F, COPPS-2 Investigators (2014) Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA 312:1016–1023CrossRefPubMedGoogle Scholar
  14. 14.
    Meurin P, Leley-Kubas S, Pierre B, Pereira B, Iliou MC, Bussiere JL, Weber H, Beugin JP, Farrokhi T, Bellemain-Appaix A, Briota L, Tabet JY Colchicine for postoperative pericardial effusion: The Post-Operative Pericardial Effusion-2 (POPE-2) study: A multicenter, double-blind, randomized trial. European Society of Cardiology 2014 Congress; August 31, 2014; Barcelona, Spainl Hot line 889Google Scholar
  15. 15.
    Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010) Controversial issues in the management of pericardial diseases. Circulation 121:916–928CrossRefPubMedGoogle Scholar
  16. 16.
    Maisch B, Seferovic PM, Ristic AD, Erbel R, Rienmuller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH, Task Force on the Diagnosis and Management of Pricardial Diseases of the European Society of Cardiology (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the european society of cardiology. Eur Heart J 25:587–610CrossRefPubMedGoogle Scholar
  17. 17.
    Lotrionte M, Biondi-Zoccai G, Imazio M, Castagno D, Moretti C, Abbate A, Agostoni P, Brucato AL, Di Pasquale P, Raatikka M, Sangiorgi G, Laudito A, Sheiban I, Gaita F (2010) International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J 160:662–670CrossRefPubMedGoogle Scholar
  18. 18.
    Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, Adler Y (2012) Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart 98:1078–1082CrossRefPubMedGoogle Scholar
  19. 19.
    Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A (2014) Colchicine for pericarditis. Cochrane Database Syst Rev 8:CD010652. doi: 10.1002/14651858.CD010652.pub2 PubMedGoogle Scholar
  20. 20.
    Imazio M, Brucato A, Belli R, Forno D, Ferro S, Trinchero R, Adler Y (2014) Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014—systematic review and meta-analysis. J Cardiovasc Med 15:840–846CrossRefGoogle Scholar
  21. 21.
    Imazio M, Adler Y (2013) Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev 18:355–360CrossRefPubMedGoogle Scholar
  22. 22.
    Authors/Task Force Members, Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristić AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W, Document Reviewers, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio AL, Carerj S, Ceconi C, Evangelista A, Flachskampf F, Giannakoulas G, Gielen S, Habib G, Kolh P, Lambrinou E, Lancellotti P, Lazaros G, Linhart A, Meurin P, Nieman K, Piepoli MF, Price S, Roos-Hesselink J, Roubille F, Ruschitzka F, Sagristà Sauleda J, Sousa-Uva M, Uwe Voigt J, Luis Zamorano J (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36:2921–2964CrossRefGoogle Scholar
  23. 23.
    Lilly LS (2013) Treatment of acute and recurrent idiopathic pericarditis. Circulation 127:1723–1726CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2016

Authors and Affiliations

  • Y.-L. Li
    • 1
  • S.-B. Qiao
    • 2
  • J.-Y. Wang
    • 3
  • Y.-M. Chen
    • 4
  • J. Luo
    • 1
  • H.-F. Zhang
    • 1
  1. 1.Health Division of Guard Bureau, General staff Department of Chinese PLABeijingChina
  2. 2.Department of CardiologyThe People’s Hospital of RizhaoRizhaoChina
  3. 3.Department of Cardiovascular SurgeryThe Second People’s Hospital of Yunnan ProvinceKunmingChina
  4. 4.Department of PediatricsBeijing Chao-Yang Hospital, Capital Medical UniversityBeijingChina

Personalised recommendations